Tags

Type your tag names separated by a space and hit enter

Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pediatrics. 2006 Apr; 117(4):1084-93.Ped

Abstract

BACKGROUND

The incidence of pertussis is increasing, especially in adolescents, attributed in part to waning of immunity after childhood immunization. Recently licensed in the United States for use in adolescents, acellular pertussis vaccines will provide an immunogenic and safe option for booster immunization against pertussis.

METHODS

This prospective, randomized, observer-blinded, multicenter, comparative study evaluated the safety and immunogenicity of a vaccine formulated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens (Tdap) compared with tetanus and diphtheria toxoids vaccine (Td) for booster immunization in adolescents. There were 4114 healthy adolescents aged 10 to 18 years who completed childhood vaccination against diphtheria, tetanus, and pertussis who were enrolled, randomized, and received study vaccine.

RESULTS

Local and general symptoms were comparable between the Tdap and Td groups. The immune response of Tdap was comparable with Td vaccine for tetanus and diphtheria seroprotection and booster responses. In addition, geometric mean concentrations of antibody to pertussis antigens, pertussis toxoid, filamentous hemagglutinin, and pertactin exceeded the antibody response elicited after infant immunization with diphtheria and tetanus toxoids and acellular pertussis antigens (DTaP) that had proven efficacy against pertussis.

CONCLUSIONS

In adolescents, the studied Tdap was safe and immunogenic and induced pertussis antibodies that were higher than those associated with efficacy in infants.

Authors+Show Affiliations

University of Rochester Medical Center, Rochester, NY 14642, USA. michael_pichichero@urmc.rochester.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16585302

Citation

Pichichero, Michael E., et al. "Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents." Pediatrics, vol. 117, no. 4, 2006, pp. 1084-93.
Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084-93.
Pichichero, M. E., Blatter, M. M., Kennedy, W. A., Hedrick, J., Descamps, D., & Friedland, L. R. (2006). Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics, 117(4), 1084-93.
Pichichero ME, et al. Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents. Pediatrics. 2006;117(4):1084-93. PubMed PMID: 16585302.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. AU - Pichichero,Michael E, AU - Blatter,Mark M, AU - Kennedy,William A, AU - Hedrick,James, AU - Descamps,Dominique, AU - Friedland,Leonard R, PY - 2006/4/6/pubmed PY - 2006/5/11/medline PY - 2006/4/6/entrez SP - 1084 EP - 93 JF - Pediatrics JO - Pediatrics VL - 117 IS - 4 N2 - BACKGROUND: The incidence of pertussis is increasing, especially in adolescents, attributed in part to waning of immunity after childhood immunization. Recently licensed in the United States for use in adolescents, acellular pertussis vaccines will provide an immunogenic and safe option for booster immunization against pertussis. METHODS: This prospective, randomized, observer-blinded, multicenter, comparative study evaluated the safety and immunogenicity of a vaccine formulated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens (Tdap) compared with tetanus and diphtheria toxoids vaccine (Td) for booster immunization in adolescents. There were 4114 healthy adolescents aged 10 to 18 years who completed childhood vaccination against diphtheria, tetanus, and pertussis who were enrolled, randomized, and received study vaccine. RESULTS: Local and general symptoms were comparable between the Tdap and Td groups. The immune response of Tdap was comparable with Td vaccine for tetanus and diphtheria seroprotection and booster responses. In addition, geometric mean concentrations of antibody to pertussis antigens, pertussis toxoid, filamentous hemagglutinin, and pertactin exceeded the antibody response elicited after infant immunization with diphtheria and tetanus toxoids and acellular pertussis antigens (DTaP) that had proven efficacy against pertussis. CONCLUSIONS: In adolescents, the studied Tdap was safe and immunogenic and induced pertussis antibodies that were higher than those associated with efficacy in infants. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/16585302/Acellular_pertussis_vaccine_booster_combined_with_diphtheria_and_tetanus_toxoids_for_adolescents_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=16585302 DB - PRIME DP - Unbound Medicine ER -